Specifically, leveraging the NanoString IO-360 panel, as well as immune-histochemistry (IHC), we have reported that tumor target antigen (CD19) expression and a predefined B-cell signature (from NanoString) associate with longer EFS with axi-cel in R/R LBCL. Here, CD19 is linked to neoplasm.